The U.S. Securities and Exchange Commission filed insider trading charges against Usama Malik, the former chief financial officer of Immunomedics Inc.
If you are not happy with the results below please do another search
50 search results for:
BioNTech should be able to adapt the German company’s coronavirus vaccine relatively quickly in response to the Omicron variant, and the next few weeks will show how urgently an upgrade is needed, CEO Ugur Sahin told the Reuters Next conference on December 3.
The World Health Organization’s chief scientist told the Reuters Next conference on December 3 the Omicron variant could become dominant because it is highly transmissible, but that a different vaccine may not be needed.
The likelihood that people will need to have an annual Covid-19 vaccine – similar to the influenza shot – is increasing, BioNTech chief executive and co-founder Ugur Sahin told the Reuters Next conference on December 3.
Swiss drug giant Novartis and Belgian pharma company UCB announced a deal to co-develop and commercialize two products targeting Parkinson’s disease, UCB0599 and UCB7853.
Vincent Colicchio – Vice President, Supply Chain and External Manufacturing for Dr. Reddy’s Laboratories – discusses supply chain, manufacturing and training issues pertaining to generic drug manufacturing.
Real Chemistry, a leading provider of data-driven, tech-enabled communication and marketing solutions for the health care sector, announced Founder and Chief Executive Officer Jim Weiss will become chairman and Shankar Narayanan will become chief executive officer and a member of the board of directors effective January 3, 2022. In addition to his role as chairman and founder of Real Chemistry, Weiss will join New Mountain Capital (NMC), Real Chemistry’s investment partner, as an executive advisor.
Germany decided on December 2 to bar the unvaccinated from all but the most essential business and the United States prepared further travel restrictions as the world scrambled to curb the Omicron variant of the coronavirus.
Astellas and Dyno Therapeutics announced a research collaboration to develop next-generation adeno-associated virus (AAV) gene therapy vectors for skeletal and cardiac muscle using Dyno’s CapsidMap platform.
Novavax Inc. said on Thursday the company could begin commercial manufacturing of a Covid-19 vaccine tailored for the Omicron coronavirus variant in January 2022, while testing whether or not its current vaccine works against the variant.